KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Notes Payables: 2014-2015

Historic Notes Payables for Regeneron Pharmaceuticals (REGN) over the last 2 years, with Dec 2015 value amounting to $1.6 million.

  • Regeneron Pharmaceuticals' Notes Payables was N/A to $1.5 billion in Q2 2020 from the same period last year, while for Jun 2020 it was $1.5 billion, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2015, which is 78.67% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Notes Payables of $1.6 million as of FY2015, which was down 78.67% from $7.5 million recorded in FY2014.
  • Over the past 5 years, Regeneron Pharmaceuticals' Notes Payables peaked at $7.5 million during FY2014, and registered a low of $1.6 million during FY2015.
  • Moreover, its 2-year median value for Notes Payables was $4.5 million (2014), whereas its average is $4.5 million.
  • Data for Regeneron Pharmaceuticals' Notes Payables shows a maximum YoY crashed of 78.67% (in 2015) over the last 5 years.
  • Regeneron Pharmaceuticals' Notes Payables (Yearly) stood at $7.5 million in 2014, then slumped by 78.67% to $1.6 million in 2015.